|
| 35012410 | Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe. | J Asthma | 2023 |
| 36123816 | Changing co-morbidity and increasing deprivation among people living with HIV: UK population-based cross-sectional study. | HIV Med | 2023 |
| 36385522 | Effects of the COVID-19 pandemic on secondary care for cardiovascular disease in the UK: an electronic health record analysis across three countries. | Eur Heart J Qual Care Clin Outcomes | 2023 |
| 37582755 | Impact of data source choice on multimorbidity measurement: a comparison study of 2.3 million individuals in the Welsh National Health Service. | BMC Med | 2023 |
| 37034358 | Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. | EClinicalMedicine | 2023 |
| 37014910 | The impact of varying the number and selection of conditions on estimated multimorbidity prevalence: A cross-sectional study using a large, primary care population dataset. | PLoS Med | 2023 |
| 36944118 | Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. | Diabetes Care | 2023 |
| 37061672 | External validation of the QLifetime cardiovascular risk prediction tool: population cohort study. | BMC Cardiovasc Disord | 2023 |
| 36997222 | Age, sex, and socioeconomic differences in multimorbidity measured in four ways: UK primary care cross-sectional analysis. | Br J Gen Pract | 2023 |
| 36610448 | Derivation and validation of the CFracture competing risk fracture prediction tool compared with QFracture in older people and people with comorbidity: a population cohort study. | Lancet Healthy Longev | 2023 |
| 37543047 | Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK. | Lancet Healthy Longev | 2023 |
| 35012410 | Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe. | J Asthma | 2023 |
| 37582755 | Impact of data source choice on multimorbidity measurement: a comparison study of 2.3 million individuals in the Welsh National Health Service. | BMC Med | 2023 |
| 37543047 | Antipsychotic drug prescribing and mortality in people with dementia before and during the COVID-19 pandemic: a retrospective cohort study in Wales, UK. | Lancet Healthy Longev | 2023 |
| 37061672 | External validation of the QLifetime cardiovascular risk prediction tool: population cohort study. | BMC Cardiovasc Disord | 2023 |
| 37014910 | The impact of varying the number and selection of conditions on estimated multimorbidity prevalence: A cross-sectional study using a large, primary care population dataset. | PLoS Med | 2023 |
| 36944118 | Cardiovascular Safety in Type 2 Diabetes With Sulfonylureas as Second-line Drugs: A Nationwide Population-Based Comparative Safety Study. | Diabetes Care | 2023 |
| 37034358 | Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. | EClinicalMedicine | 2023 |
| 36997222 | Age, sex, and socioeconomic differences in multimorbidity measured in four ways: UK primary care cross-sectional analysis. | Br J Gen Pract | 2023 |
| 36610448 | Derivation and validation of the CFracture competing risk fracture prediction tool compared with QFracture in older people and people with comorbidity: a population cohort study. | Lancet Healthy Longev | 2023 |
| 36123816 | Changing co-morbidity and increasing deprivation among people living with HIV: UK population-based cross-sectional study. | HIV Med | 2023 |
| 36385522 | Effects of the COVID-19 pandemic on secondary care for cardiovascular disease in the UK: an electronic health record analysis across three countries. | Eur Heart J Qual Care Clin Outcomes | 2023 |
| 35094685 | Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network. | BMC Med Res Methodol | 2022 |
| 35653017 | Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study. | Drug Saf | 2022 |
| 35505353 | Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study. | BMC Med | 2022 |
| 35497059 | Health conditions in adults with HIV compared with the general population: A population-based cross-sectional analysis. | EClinicalMedicine | 2022 |
| 35854309 | Patient outcomes following AKI and AKD: a population-based cohort study. | BMC Med | 2022 |
| 36419195 | Assessing the impact of a national clinical guideline for the management of chronic pain on opioid prescribing rates: a controlled interrupted time series analysis. | Implement Sci | 2022 |
| 36188566 | International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients. | Front Pharmacol | 2022 |
| 36936595 | Effect of competing mortality risks on predictive performance of the QFracture risk prediction tool for major osteoporotic fracture and hip fracture: external validation cohort study in a UK primary care population. | BMJ Med | 2022 |
| 35094685 | Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network. | BMC Med Res Methodol | 2022 |
| 35345821 | Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. | Clin Epidemiol | 2022 |
| 35653017 | Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study. | Drug Saf | 2022 |
| 35505353 | Predictive performance of a competing risk cardiovascular prediction tool CRISK compared to QRISK3 in older people and those with comorbidity: population cohort study. | BMC Med | 2022 |
| 35345821 | Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. | Clin Epidemiol | 2022 |
| 35497059 | Health conditions in adults with HIV compared with the general population: A population-based cross-sectional analysis. | EClinicalMedicine | 2022 |
| 35854309 | Patient outcomes following AKI and AKD: a population-based cohort study. | BMC Med | 2022 |
| 36936595 | Effect of competing mortality risks on predictive performance of the QFracture risk prediction tool for major osteoporotic fracture and hip fracture: external validation cohort study in a UK primary care population. | BMJ Med | 2022 |
| 36419195 | Assessing the impact of a national clinical guideline for the management of chronic pain on opioid prescribing rates: a controlled interrupted time series analysis. | Implement Sci | 2022 |
| 36188566 | International cohort study indicates no association between alpha-1 blockers and susceptibility to COVID-19 in benign prostatic hyperplasia patients. | Front Pharmacol | 2022 |
| 33125664 | Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Stakeholder Safety Engagement Tool (ASSET). | Drug Saf | 2021 |
| 33965593 | Intolerance to Angiotensin Converting Enzyme Inhibitors in Asthma and the General Population: A UK Population-Based Cohort Study. | J Allergy Clin Immunol Pract | 2021 |
| 33688639 | Unraveling COVID-19: a large-scale characterization of 4.5 million COVID-19 cases using CHARYBDIS. | Res Sq | 2021 |
| 33791740 | Alpha-1 blockers and susceptibility to COVID-19 in benign prostate hyperplasia patients : an international cohort study. | medRxiv | 2021 |
| 34272262 | Characteristics and Outcomes of Over 300,000 Patients with COVID-19 and History of Cancer in the United States and Spain. | Cancer Epidemiol Biomarkers Prev | 2021 |
| 34049958 | Thirty-Day Outcomes of Children and Adolescents With COVID-19: An International Experience. | Pediatrics | 2021 |
| 34000735 | Commentary: Obstetric oxytocin exposure and risk of attention-deficit hyperactivity disorder and autism spectrum disorder in offspring-case closed. | Int J Epidemiol | 2021 |
| 33783857 | Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations. | Br J Clin Pharmacol | 2021 |
| 34267326 | Characteristics and outcomes of 627 044 COVID-19 patients living with and without obesity in the United States, Spain, and the United Kingdom. | Int J Obes (Lond) | 2021 |
| 34100008 | Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study. | Lancet Healthy Longev | 2021 |